Ontology highlight
ABSTRACT:
SUBMITTER: Gutting T
PROVIDER: S-EPMC8115557 | biostudies-literature | 2021 May
REPOSITORIES: biostudies-literature
Gutting Tobias T Hauber Veronika V Pahl Jens J Klapproth Kay K Wu Wenyue W Dobrota Ioana I Herweck Frank F Reichling Juliane J Helm Laura L Schroeder Torsten T Li Beifang B Weidner Philip P Zhan Tianzuo T Eckardt Maximilian M Betge Johannes J Belle Sebastian S Sticht Carsten C Gaiser Timo T Boutros Michael M Ebert Matthias P A MPA Cerwenka Adelheid A Burgermeister Elke E
Oncoimmunology 20210505 1
Only a small subset of colorectal cancer (CRC) patients benefits from immunotherapies, comprising blocking antibodies (Abs) against checkpoint receptor "programmed-cell-death-1" (PD1) and its ligand (PD-L1), because most cases lack the required mutational burden and neo-antigen load caused by microsatellite instability (MSI) and/or an inflamed, immune cell-infiltrated PD-L1+ tumor microenvironment. Peroxisome proliferator-activated-receptor-gamma (PPARγ), a metabolic transcription factor stimula ...[more]